ProfileGDS5678 / 1450058_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 27% 39% 27% 29% 28% 27% 27% 27% 31% 26% 26% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8931538
GSM967853U87-EV human glioblastoma xenograft - Control 22.6238827
GSM967854U87-EV human glioblastoma xenograft - Control 32.8867839
GSM967855U87-EV human glioblastoma xenograft - Control 42.5714327
GSM967856U87-EV human glioblastoma xenograft - Control 52.6179829
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7061628
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6652927
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5946927
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5903827
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7004931
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5914926
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5786726
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6121827
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6218927